JP2016510748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510748A5 JP2016510748A5 JP2015561618A JP2015561618A JP2016510748A5 JP 2016510748 A5 JP2016510748 A5 JP 2016510748A5 JP 2015561618 A JP2015561618 A JP 2015561618A JP 2015561618 A JP2015561618 A JP 2015561618A JP 2016510748 A5 JP2016510748 A5 JP 2016510748A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- alkyl
- linear
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772885P | 2013-03-05 | 2013-03-05 | |
| US61/772,885 | 2013-03-05 | ||
| PCT/US2014/020858 WO2014138279A1 (en) | 2013-03-05 | 2014-03-05 | Compounds for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017755A Division JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510748A JP2016510748A (ja) | 2016-04-11 |
| JP2016510748A5 true JP2016510748A5 (enExample) | 2017-04-06 |
| JP6835472B2 JP6835472B2 (ja) | 2021-02-24 |
Family
ID=51491914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561618A Expired - Fee Related JP6835472B2 (ja) | 2013-03-05 | 2014-03-05 | 癌の処置のための組成物 |
| JP2019017755A Pending JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017755A Pending JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10022356B2 (enExample) |
| EP (1) | EP2964028A4 (enExample) |
| JP (2) | JP6835472B2 (enExample) |
| KR (1) | KR102246652B1 (enExample) |
| CN (2) | CN105163584B (enExample) |
| AU (2) | AU2014225761B2 (enExample) |
| CA (1) | CA2904338C (enExample) |
| IL (1) | IL241232B (enExample) |
| MX (2) | MX375059B (enExample) |
| RU (1) | RU2708247C2 (enExample) |
| WO (1) | WO2014138279A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029408B2 (en) * | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) * | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
| MX379271B (es) | 2014-05-06 | 2025-03-11 | Gtx Inc | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. |
| CN104434924B (zh) * | 2014-11-10 | 2016-09-14 | 暨南大学 | 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用 |
| CA2972189A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2016130917A1 (en) * | 2015-02-12 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| IL256111B2 (en) * | 2015-06-05 | 2023-09-01 | Univ Illinois | Treatment of pac combinations |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| US20180369203A1 (en) * | 2015-07-09 | 2018-12-27 | The Jackson Laboratory | Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor |
| WO2017024207A1 (en) * | 2015-08-06 | 2017-02-09 | The Wistar Institute Of Anatomy And Biology | Combination therapies targeting mitochondrial biogenesis for cancer therapy |
| US10821112B2 (en) | 2016-03-16 | 2020-11-03 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| WO2017200826A1 (en) * | 2016-05-16 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Assays and compounds for treatment of cancer |
| EP3571200B8 (en) | 2017-01-17 | 2022-08-03 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP7140103B2 (ja) * | 2017-03-10 | 2022-09-21 | コニカミノルタ株式会社 | 治療有効性の予測方法 |
| US11883491B2 (en) | 2017-05-03 | 2024-01-30 | St. Jude Children's Research Hospital, Inc. | Compositions and methods for prevention and treatment of hearing loss |
| IL274663B2 (en) | 2017-11-17 | 2024-01-01 | Univ Illinois | Cancer therapy by degrading dual mek signaling |
| CN108218855A (zh) * | 2018-03-12 | 2018-06-29 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| WO2019222385A1 (en) * | 2018-05-15 | 2019-11-21 | University Of Tennessee Research Foundation | Compounds for treatment of triple negative breast cancer and ovarian cancer |
| US20190374512A1 (en) * | 2018-05-15 | 2019-12-12 | University Of Tennessee Research Foundation | Compounds for treatment of pancreatic cancer |
| CN113329749B (zh) | 2018-10-05 | 2025-02-11 | 伊利诺伊大学董事会 | 用于治疗葡萄膜黑色素瘤的联合疗法 |
| GB201913124D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| JP2023513015A (ja) * | 2020-01-31 | 2023-03-30 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| CN113440616A (zh) * | 2020-03-25 | 2021-09-28 | 上海科州药物研发有限公司 | Ras或raf突变型癌症的联合疗法 |
| WO2022006512A1 (en) * | 2020-07-02 | 2022-01-06 | The Board Of Regents Of The University Of Texas System | Methods of treatment for melanoma |
| WO2022067185A1 (en) * | 2020-09-27 | 2022-03-31 | Veru Inc. | Methods of treating prostate cancer with minimal side effects |
| WO2022131667A1 (ko) * | 2020-12-18 | 2022-06-23 | 경희대학교 산학협력단 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| CN115504964A (zh) * | 2022-04-12 | 2022-12-23 | 海创药业股份有限公司 | 氘代杂环酮类化合物及其用途 |
| CN117143081B (zh) * | 2022-05-24 | 2025-08-01 | 赣南医科大学 | 一种Sabizabulin的制备方法 |
| WO2024036114A2 (en) * | 2022-08-08 | 2024-02-15 | The Regents Of The University Of California | Combination therapy including cox-2 inhibitor for the treatment of cancer |
| WO2024186641A1 (en) * | 2023-03-03 | 2024-09-12 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN119409641A (zh) * | 2024-11-05 | 2025-02-11 | 杭州电子科技大学 | 一种磺酰基衍生物和用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| JP2829451B2 (ja) | 1990-11-30 | 1998-11-25 | 大塚製薬株式会社 | 活性酸素抑制剤 |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| JP2550915B2 (ja) | 1994-06-21 | 1996-11-06 | 日本電気株式会社 | 印刷配線板の表面保護剤および表面保護膜の形成方法 |
| EP1347971B1 (en) | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| WO2003027105A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors |
| US20040267017A1 (en) | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US7071218B2 (en) | 2001-11-15 | 2006-07-04 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| AU2004210711B2 (en) | 2003-02-12 | 2010-07-08 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| WO2004093873A1 (en) | 2003-04-17 | 2004-11-04 | Janssen Pharmaceutica, N.V. | 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer |
| WO2004103960A2 (en) | 2003-05-16 | 2004-12-02 | Ambit Biosciences Corporation | Compounds and uses thereof |
| CN1902184A (zh) | 2003-11-18 | 2007-01-24 | 田纳西大学研究基金会 | 噻唑烷酮酰胺、噻唑烷羧酸酰胺、其制备方法及其用途 |
| WO2005058834A2 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
| US20070191448A1 (en) | 2004-03-08 | 2007-08-16 | Robert Zelle | Ion channel modulators |
| WO2006002119A2 (en) | 2004-06-18 | 2006-01-05 | Gpc Biotech, Inc. | Kinase inhibitors for treating cancers |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| EP2395004B1 (en) * | 2005-06-22 | 2016-01-20 | Plexxikon Inc. | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| EP2025347A4 (en) | 2006-05-15 | 2010-08-11 | Takeda Pharmaceutical | PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER |
| US7464893B2 (en) * | 2006-06-30 | 2008-12-16 | Per Spjut | Method of using a cord holder |
| KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
| US9029408B2 (en) * | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US8822513B2 (en) * | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| US9447049B2 (en) * | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| PL3560498T3 (pl) * | 2009-10-16 | 2022-12-12 | Novartis Ag | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
| RU2581367C2 (ru) * | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
| US8426418B2 (en) | 2010-08-27 | 2013-04-23 | CollabRx Inc. | Method to treat melanoma in BRAF inhibitor-resistant subjects |
| CN103443725B (zh) | 2011-03-29 | 2015-07-29 | 三菱电机株式会社 | 伺服控制装置的异常诊断装置及异常诊断系统 |
| SG194052A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and erlotinib, and methods of use |
| ME02316B (me) * | 2011-04-07 | 2016-06-20 | Bayer Ip Gmbh | Imidazopiridazini kao inhibitori akt kinaze |
| JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
-
2014
- 2014-03-05 JP JP2015561618A patent/JP6835472B2/ja not_active Expired - Fee Related
- 2014-03-05 WO PCT/US2014/020858 patent/WO2014138279A1/en not_active Ceased
- 2014-03-05 US US14/773,265 patent/US10022356B2/en active Active
- 2014-03-05 EP EP14760577.8A patent/EP2964028A4/en not_active Withdrawn
- 2014-03-05 KR KR1020157027404A patent/KR102246652B1/ko not_active Expired - Fee Related
- 2014-03-05 MX MX2015011713A patent/MX375059B/es active IP Right Grant
- 2014-03-05 CA CA2904338A patent/CA2904338C/en active Active
- 2014-03-05 CN CN201480025267.4A patent/CN105163584B/zh active Active
- 2014-03-05 AU AU2014225761A patent/AU2014225761B2/en not_active Ceased
- 2014-03-05 CN CN201811371741.5A patent/CN109568312A/zh active Pending
- 2014-03-05 RU RU2015142102A patent/RU2708247C2/ru active
-
2015
- 2015-09-04 MX MX2020009256A patent/MX2020009256A/es unknown
- 2015-09-06 IL IL241232A patent/IL241232B/en active IP Right Grant
-
2018
- 2018-07-12 US US16/033,953 patent/US10525037B2/en active Active
- 2018-09-06 AU AU2018226470A patent/AU2018226470B2/en not_active Ceased
-
2019
- 2019-02-04 JP JP2019017755A patent/JP2019077727A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510748A5 (enExample) | ||
| RU2015142102A (ru) | Соединение для лечения рака | |
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2009514880A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| JP2013521281A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2018507191A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016502544A5 (enExample) | ||
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| JP2016503414A5 (enExample) | ||
| JP2019529518A5 (enExample) | ||
| TN2012000110A1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP2017534583A5 (enExample) | ||
| JP2020502094A5 (enExample) | ||
| JP2011521938A5 (enExample) | ||
| JP2016512831A5 (enExample) | ||
| JP2016522254A5 (enExample) |